Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of ABI-H2158 in Healthy Volunteers and Chronic Hepatitis B
NCT03714152Phase 1Completed
- Sponsor
- Assembly Biosciences, Inc.
- Start
- Nov 2018
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing ABI-H2158 with Placebo (2 arms). Primary endpoint: Number of healthy volunteers and patients with chronic HBV infection with treatment-related adverse events up to 28 days. Started Nov 2018; status: completed.
02
Drugs
firzacorvir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03714152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03714152.